Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study | Zendy

Fabrizio Cantini | Zendy; Niccoli Laura | Zendy; Cassara | Zendy; Kaloudi | Zendy; Nannini Carlotta | Zendy

Open Access

Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study

Author(s) -

Fabrizio Cantini,

Niccoli Laura,

Cassara,

Kaloudi,

Nannini Carlotta

Publication year - 2012

Publication title -

biologics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.948

H-Index - 38

eISSN - 1177-5491

pISSN - 1177-5475

DOI - 10.2147/btt.s31145

Subject(s) - medicine , psoriatic arthritis , adalimumab , rheumatoid arthritis , psoriasis , rheumatology , methotrexate , arthritis , etanercept , adverse effect , surgery , gastroenterology , dermatology

The primary purpose of this study was to evaluate the proportion of psoriatic arthritis (PsA) patients maintaining clinical remission after adalimumab (ADA) dose reduction compared with patients with rheumatoid arthritis. Secondary purposes include evaluating the proportion of PsA patients who achieve remission, the duration of remission after ADA dose reduction, time to relapse, psoriasis course, and the frequency of adverse events at the end of follow-up.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research